scispace - formally typeset
J

Jeff Gentry

Researcher at Broad Institute

Publications -  14
Citations -  25106

Jeff Gentry is an academic researcher from Broad Institute. The author has contributed to research in topics: Bioconductor & Constraint (information theory). The author has an hindex of 8, co-authored 14 publications receiving 20095 citations. Previous affiliations of Jeff Gentry include Harvard University.

Papers
More filters
Journal ArticleDOI

The mutational constraint spectrum quantified from variation in 141,456 humans

TL;DR: A catalogue of predicted loss-of-function variants in 125,748 whole-exome and 15,708 whole-genome sequencing datasets from the Genome Aggregation Database (gnomAD) reveals the spectrum of mutational constraints that affect these human protein-coding genes.
Journal ArticleDOI

Integrated genomic characterization of endometrial carcinoma

Gad Getz, +283 more
- 02 May 2013 - 
TL;DR: In this paper, the authors performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array-and-sequencing-based technologies, and classified them into four categories: POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy number high.
Journal ArticleDOI

Comprehensivemolecular characterization of clear cell renal cell carcinoma

Chad J. Creighton, +291 more
- 28 Aug 2013 - 
TL;DR: Remodelling cellular metabolism constitutes a recurrent pattern in ccRCC that correlates with tumour stage and severity and offers new views on the opportunities for disease treatment.
Posted ContentDOI

Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes

Konrad J. Karczewski, +95 more
- 30 Jan 2019 - 
TL;DR: Using an improved human mutation rate model, human protein-coding genes are classified along a spectrum representing tolerance to inactivation, validate this classification using data from model organisms and engineered human cells, and show that it can be used to improve gene discovery power for both common and rare diseases.